5
Starsource Multitrade
CHEMOPHARMALABORATORIESLTD NSE
Starsource Multitrade
HealthcareNSE: CHEMOPHARMALABORATORIESLTD BSE: 506365 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹11.00 Cr
Volatility
Moderate
P/E Ratio
-282.6
EBITDA
₹-1.30 Cr
Return on Equity
-39.44%
Debt to Equity
0
Book Value
₹8.6
EPS
₹7.14
52W High
₹152.9
52W Low
₹72
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company is almost debt free.
Weaknesses
5- Stock is trading at 8.46 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 27.9%
- Company has a low return on equity of 5.09% over last 3 years.
- Company has high debtors of 337 days.
Growth Rate
Revenue Growth
—
Net Income Growth
100% higher than
3Y
Cash Flow Change
-103% lower than
3Y
ROE
—
ROCE
—
EBITDA Margin (Avg.)
—
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.53 | 0 | 0 | 0.07 |
| Expenses | 0.05 | 0.02 | 0.02 | 0.1 | 0.05 | 0.02 | 0.02 | 0.02 | 11.83 | 0.43 | 0.09 | 0.07 | 0.05 |
| Operating Profit | -0.05 | -0.02 | -0.02 | -0.1 | -0.05 | -0.02 | -0.02 | -0.02 | -11.83 | 0.1 | -0.09 | -0.07 | 0.02 |
| OPM % | — | — | — | — | — | — | — | — | — | 18.87% | — | — | 28.57% |
| Other Income | 0.43 | 0.46 | 0.7 | 0.25 | 0.3 | 0.63 | -0.15 | -0.16 | 0.02 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0.38 | 0.44 | 0.68 | 0.15 | 0.25 | 0.61 | -0.17 | -0.18 | -11.81 | 0.1 | -0.09 | -0.07 | 0.02 |
| Tax % | 0% | 0% | 0% | 293.33% | 0% | 0% | 0% | 88.89% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | 0.38 | 0.44 | 0.68 | -0.29 | 0.25 | 0.61 | -0.17 | -0.34 | -11.81 | 0.1 | -0.09 | -0.07 | 0.02 |
| EPS in Rs | 2.53 | 2.93 | 4.53 | -1.93 | 1.67 | 4.07 | -1.13 | -2.27 | -78.73 | 0.67 | -0.6 | -0.47 | 0.13 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.53 | 0.6 |
| Expenses | 0.12 | 0.17 | 0.27 | 0.34 | 0.56 | 0.48 | 0.34 | 0.41 | 0.2 | 0.19 | 0.12 | 0.53 | 0.64 |
| Operating Profit | -0.12 | -0.17 | -0.27 | -0.34 | -0.56 | -0.48 | -0.34 | -0.41 | -0.2 | -0.19 | -0.12 | 0 | -0.04 |
| OPM % | — | — | — | — | — | — | — | — | — | — | — | 0% | -6.67% |
| Other Income | 0.5 | 0.49 | 5.61 | 1.11 | 0.82 | 1 | 0.67 | 0.79 | 0.3 | 1.84 | 0.62 | -11.85 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0 | 0 |
| PBT | 0.38 | 0.32 | 5.34 | 0.77 | 0.26 | 0.5 | 0.31 | 0.36 | 0.08 | 1.64 | 0.49 | -11.85 | -0.04 |
| Tax % | 26.32% | 31.25% | 12.17% | 85.71% | 19.23% | 16% | 19.35% | -55.56% | 37.5% | 26.83% | 32.65% | 0% | — |
| Net Profit | 0.28 | 0.22 | 4.68 | 0.1 | 0.21 | 0.42 | 0.25 | 0.56 | 0.05 | 1.2 | 0.34 | -11.85 | -0.04 |
| EPS in Rs | 1.87 | 1.47 | 31.2 | 0.67 | 1.4 | 2.8 | 1.67 | 3.73 | 0.33 | 8 | 2.27 | -79 | -0.27 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 |
| Reserves | 3.62 | 3.84 | 8.52 | 8.62 | 8.83 | 9.24 | 9.49 | 10.05 | 10.1 | 11.3 | 11.64 | -0.21 |
| Borrowings | 0 | 0 | 0.12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 0.46 | 0.2 | 0.58 | 0.13 | 0.09 | 0.22 | 0.06 | 0.11 | 0.02 | 0.21 | 0.21 | 0.53 |
| Total Liabilities | 5.58 | 5.54 | 10.72 | 10.25 | 10.42 | 10.96 | 11.05 | 11.66 | 11.62 | 13.01 | 13.35 | 1.82 |
| Fixed Assets | 0 | 0 | 0.01 | 0 | 0 | 0.07 | 0.05 | 0.04 | 0.03 | 0.02 | 0.01 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 1.68 | 1.68 | 0.02 | 0.02 | 0.04 | 0.02 | 0.04 | 2.94 | 3.03 | 4.4 | 0.01 | 0.01 |
| Other Assets | 3.9 | 3.86 | 10.69 | 10.23 | 10.38 | 10.87 | 10.96 | 8.68 | 8.56 | 8.59 | 13.33 | 1.81 |
| Total Assets | 5.58 | 5.54 | 10.72 | 10.25 | 10.42 | 10.96 | 11.05 | 11.66 | 11.62 | 13.01 | 13.35 | 1.82 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -0.05 | -0.43 | 6.41 | -1.66 | -5.48 | 4.83 | -0.41 | -0.33 | -0.68 | 0.72 | -0.28 | -10.62 |
| Investing | 0.25 | 0.49 | 0.52 | 1.08 | 0.79 | 1.01 | -0.19 | 0.97 | 0.63 | -0.52 | 10.46 | 0.01 |
| Financing | 0 | 0 | -0.5 | 1.37 | 0 | 0 | 1.96 | -2.12 | -0.08 | -0.15 | -0.16 | 0 |
| Net Cash Flow | 0.2 | 0.06 | 6.43 | 0.79 | -4.7 | 5.84 | 1.36 | -1.49 | -0.13 | 0.05 | 10.02 | -10.61 |
| Free Cash Flow | -0.05 | -0.43 | 6.41 | -1.66 | -5.48 | 4.83 | -0.41 | -0.33 | -0.68 | 0.72 | -0.28 | -10.62 |
| CFO/OP | -25 | 206 | -2,615 | 294 | 970 | -1,023 | 94 | 66 | 335 | -468 | 67 | — |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | — | — | — | — | — | — | — | — | — | — | — | 337 |
| Inventory Days | — | — | — | — | — | — | — | — | — | — | — | 0 |
| Cash Conversion Cycle | — | — | — | — | — | — | — | — | — | — | — | 337 |
| Working Capital Days | — | — | — | — | — | — | — | — | — | — | — | 875 |
| ROCE % | 7.62% | 6.12% | 3.62% | 7.6% | 2.54% | 4.75% | 2.85% | 1.33% | 0.78% | 13.28% | 5.17% | 0.28% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Starsource Multitrade insights
51 extracted metrics + investor summaries across FY10–FY26.
Documents
1
Compliances-Reg.24(A)-Annual Secretarial Compliance
15 Apr - Company says Annual Secretarial Compliance Report is not applicable for FY2026 under Regulation 15(2). 15 Apr - Company says Annual Secretarial Compliance Report is not applicable for FY2026 under Regulation 15(2).
2
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
15 Apr - Starsource Multitrade confirms it is outside Large Corporate criteria as of March 31, 2026. 15 Apr - Starsource Multitrade confirms it is outside Large Corporate criteria as of March 31, 2026.
3
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
6 Apr - Regulation 74(5) compliance certificate submitted for quarter ended March 31, 2026. 6 Apr - Regulation 74(5) compliance certificate submitted for quarter ended March 31, 2026.
4
Reply To Clarification On Price Movement Sought By BSE Limited
1 Apr - Company replies to BSE on share price movement, says market-driven and compliant with Regulation 30. 1 Apr - Company replies to BSE on share price movement, says market-driven and compliant with Regulation 30.
Frequently Asked Questions about Starsource Multitrade
What does Starsource Multitrade Ltd do?
The Chemo Pharma Laboratories Limited was established in 1942 and was making Pharmaceuticals and bulk drugs. However due to increased competition, Company disposed the business. Company is in advanced stage of negotiation to diversify and take over a sick company[1]
Where is Starsource Multitrade Ltd (506365) listed?
Starsource Multitrade Ltd trades as CHEMOPHARMALABORATORIESLTD on the NSE and under code 506365 on the BSE.
Which sector does Starsource Multitrade Ltd belong to?
Starsource Multitrade Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Starsource Multitrade Ltd?
Starsource Multitrade Ltd has a market capitalisation of ₹11 Cr, which places it in the Small Cap band.
What is the PE ratio of Starsource Multitrade Ltd?
Starsource Multitrade Ltd trades at a PE ratio of -282.60, on earnings per share of ₹7.14, against a book value of ₹8.6 per share.
What is the 52-week high and low of Starsource Multitrade Ltd?
Over the last 52 weeks Starsource Multitrade Ltd has traded between ₹72 and ₹152.9.
What is the Return on Equity (ROE) of Starsource Multitrade Ltd?
Starsource Multitrade Ltd reported a return on equity of -39.44%. Its debt-to-equity ratio is 0.00.
Company Information
The Chemo Pharma Laboratories Limited was established in 1942 and was making Pharmaceuticals and bulk drugs. However due to increased competition, Company disposed the business. Company is in advanced stage of negotiation to diversify and take over a sick company[1]
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/506365.md for Starsource Multitrade Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.